Cefminox (CMNX) is a new cephamycin antibiotic showing broad-spectrum activity against Gram-negative bacteria like E. coli and K. pneumoniae. Clinical trials indicated moderate efficacy in treating infections, with no observed side effects.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: